[14C] Study to Investigate the Mass Balance and Biotransformation of WPV01 in Healthy Adult Chinese Male Participants

Inclusion Criteria: * Healthy adult males * Participants aged ≥18 years and ≤55 years old * Body weight: Body mass index (BMI) between 19.0 and 26.0 kg/m2 (including borderline values), body weight no less than 50.0 kg. * Voluntarily participate in the clinical trial and sign the informed consent * Able to communicate well with the investigator and able to complete the trial in accordance with the protocol Exclusion Criteria: * Participants who have abnormalities and clinical significance after comprehensive physical examination, vital signs, routine laboratory tests, thyroid function, chest CT, abdominal ultrasound, etc. * Participants whose 12-lead electrocardiogram test results show corrected QT interval ≥450 msec * Participants who is positive for Hepatitis B Surface Antigen, Hepatitis C Antibody, HIV Antibody and Syphilis Antibody * Participants who have used any drug that inhibits or induces hepatic drug metabolizing enzymes within 30 days prior to the screening period * Participants who have used any prescription medication, over-the-counter medication, herbal or dietary supplements, such as vitamins, calcium supplements, within 14 days prior to the screening period * Participants who have a history of any clinically serious disease or disease/condition that, in the opinion of the investigator, may affect the results of the test, including, but not limited to, a history of circulatory, respiratory, endocrine, neurological, gastrointestinal, urological, or hematological, immunological, psychiatric, and metabolic disorders * Participants who have any condition that may affect drug absorption, e.g., gastrectomy, cholecystectomy, gastric bypass, duodenotomy, colectomy, history of inflammatory bowel disease * Participants who have history of organic heart disease, heart failure, myocardial infarction, angina pectoris, unexplained arrhythmia, ventricular tachycardia, atrioventricular block, QT prolongation syndrome, or symptoms of QT prolongation syndrome, and a family history of the disease (as evidenced by genetic predisposition or by the death of a close family member from a cardiac cause at a young age). * Participants who have undergone major surgery within 6 months prior to the screening period or whose surgical incisions have not completely healed; major surgery includes, but is not limited to, any surgery with significant risk of hemorrhage, prolonged general anesthesia, or incisional biopsy or significant traumatic injury * Participants who have specific allergic history, such as those with a known history of allergy to two or more substances; or those who, in the judgment of the investigator, may be allergic to the test drug or its excipients * Participants who have perianal disease with regular/ongoing blood in stool, irritable bowel syndrome, inflammatory bowel disease * Participants who have habitual constipation or diarrhea * Participants who are alcohol abusers or regularly drink alcohol in the 6 months prior to the screening period, i.e., more than 14 units of alcohol per week (1 unit = 360 mL of beer or 45 mL of spirits at 40% alcohol by volume or 150 mL of wine); or an alcohol breath test result of \>0 mg/dL at the time of the screening period * Participants who smoked \>5 cigarettes per day in the 3 months prior to the screening period or habitually used nicotine-containing products and were unable to quit during the trial period * Participants who are substance abusers or use soft drugs (e.g., marijuana) in the 3 months prior to the screening period or use of hard drugs (e.g., cocaine, amphetamines, phenylcyclohexylpiperidine, etc.) in the 1 year prior to the screening period; or a positive urine drug test at the screening period * Participants who consume grapefruit juice or excessive amounts of tea, coffee and/or caffeinated beverages that cannot be stopped during the trial period * Participants who are exposed to radiation for prolonged periods of time; or who have had significant radiation exposure (≥2 chest/abdominal CTs, or ≥3 other types of X-rays) or participated in radiopharmaceutical labeling tests within 1 year prior to testing * Participants who are with a history of needle and blood sickness, those who have difficulty in blood collection or cannot tolerate venipuncture blood collection * Participation in any other clinical trial (including clinical trials such as drugs and devices) within 3 months prior to the screening period * Participants who have vaccinated within 1 month prior to screening or scheduled to be vaccinated during the trial period * Participants who plan to have children or donate sperm during the trial and within 1 year after completion of the trial, or who do not agree that the subject and his/her spouse should use strict contraception during the trial and within 1 year after completion of the trial * Participants who have had blood loss or donated up to 400 mL of blood within 3 months prior to the screening period, or those who have received a blood transfusion within 1 month * Participants who, in the opinion of the investigator, have any factors that make participation in this trial inappropriate